The trial showed that the silencing of FGFR4 might affect the growth characteristics of GC cells (reduced invasiveness, increased apoptosis, decreased ability to proliferate), which may serve as a potential future target [63]. The gene discussed is FGFR4; the disease is gastric cancer.